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Circulating trimethylamine-N-oxide (TMAO) levels
are strongly associated with atherosclerosis. We
now examine genetic, dietary, and hormonal factors
regulating TMAO levels. We demonstrate that two
flavin mono-oxygenase family members, FMO1 and
FMO3, oxidize trimethylamine (TMA), derived from
gut flora metabolism of choline, to TMAO. Further,
we show that FMO3 exhibits 10-fold higher specific
activity than FMO1. FMO3 overexpression in mice
significantly increases plasma TMAO levels while
silencing FMO3 decreases TMAO levels. In both hu-
mans andmice, hepatic FMO3 expression is reduced
inmales compared to females. Inmice, this reduction
in FMO3 expression is due primarily to downregula-
tion by androgens. FMO3 expression is induced by
dietary bile acids by a mechanism that involves the
farnesoid X receptor (FXR), a bile acid-activated
nuclear receptor. Analysis of natural genetic variation
among inbred strains of mice indicates that FMO3
and TMAO are significantly correlated, and TMAO
levels explain 11% of the variation in atherosclerosis.
INTRODUCTION
Recently, plasma trimethylamine-N-oxide (TMAO) was identified
as a metabolite strongly associated with atherosclerosis in
a large case-control cohort for cardiovascular disease (CVD),
and studies in mice indicated a causal relationship (WangCet al., 2011). TMAO is derived from dietary choline through the
action of gut flora, which metabolize choline to trimethylamine
(TMA), a gas that is then absorbed into the circulation and further
metabolized to TMAO. Likely candidates for the conversion of
TMA to TMAO are members of the flavin mono-oxygenase
(FMO) family. In particular, FMO3 has been implicated in the
oxidation of TMA, since individuals with mutations in FMO3
present with accumulation of TMA levels, causing fish malodor
syndrome (Treacy et al., 1998). TMAO appears to contribute
to the development of atherosclerosis in part by promoting
cholesterol accumulation within macrophages, perhaps by
inducing scavenger receptors such as CD36 and SRA1, both
of which are involved in the uptake of modified lipoproteins
(Wang et al., 2011). One crucial question is how TMAO influences
cellular metabolism andwhether this is direct or indirect. Another
important question relates to the nature of the variations in
plasma TMAO levels in human populations and whether modu-
lating TMAO levels can result in reduced risk of atherosclerosis.
We now report studies of the metabolism of TMA and TMAO
inmice and humans.We examine the activities of the FMO family
members and show that FMO3 is the most active in metaboliz-
ing TMA to TMAO. Using transgenic and adenoviral approaches,
we show that upregulation of hepatic FMO3 decreases TMA
and increases TMAO levels in the circulation, while antisense-
mediated silencing of FMO3 increases TMA and decreases
TMAO levels. We further show that FMO3 is dramatically down-
regulated by testosterone in mice, suggesting a mechanism for
the greater susceptibility of female mice to atherosclerosis
as compared to males, and suggesting that FMO3 expression
is modestly decreased in males as compared to females in
human populations. We also find that FMO3 is dramatically up-
regulated by bile acids and that this is mediated by the action








Figure 1. FMO3 Is the Major FMO Family Member Responsible for the Conversion of TMA to TMAO
(A–D) Overexpression of untagged or FLAG-tagged human FMO1–FMO5 in HEK292Ad cells.
(A) Western blotting analysis of FLAG-tagged FMO1–FMO5 transfected into HEK293Ad cells. GFP was cotransfected to normalize transfection efficiency.
(B) FMO3 mRNA levels were determined by RT-qPCR and normalized to GFP mRNA levels.
(C and D) TMAO and TMA levels were determined in the media of transfected cells treated with d9-TMA and then analyzed for d9-TMA and d9-TMAO levels using
mass spectrometry (see the Experimental Procedures). TMAO production was determined from triplicate wells for each condition and normalized to the amount
of protein per well.
(E) Relative specific activity of FMO1–FMO5 determined by dividing normalized TMAO levels by relative FMO protein levels calculated by densitometry analysis
and expressed relative to FLAG-FMO3 activity.
(F) Relative Fmo3 mRNA levels in various mouse tissues from C57BL/6 mice (n = 3 mice/sex). Expression was determined by RT-qPCR and was normalized to
36B4 expression levels.
(G) Relative abundance of FMO1–FMO3 determined by RNA-Seq analysis from male and female C57BL/6 mice.
(H) Relative FMO3 expression in human liver determined by microarray expression profile from 317 Caucasian human individuals segregated by sex.
(I) RT-qPCR analysis of hepatic mRNA levels from human liver biopsies obtained as described in the Experimental Procedures. Data are presented as mean ±
SEM. Significance was measured with Student’s t test. *p < 0.05 and ***p < 0.001.
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mice. The results indicate that FMO3 contributes significantly
to TMAO levels, that other factors must also be involved, and
that TMAOexplains about 11%of the variation in atherosclerosis
susceptibility among common inbred strains of mice.
RESULTS
Expression Levels and Activities of Flavin
Mono-oxygenase Family Members
Members of the FMO family are strong candidates for the
conversion of TMA to TMAO (Treacy et al., 1998), and the five
members of the family, FMO1, FMO2, FMO3, FMO4, and50 Cell Metabolism 17, 49–60, January 8, 2013 ª2013 Elsevier Inc.FMO5, exhibit approximately 50% amino acid sequence
identity, with high sequence conservation between mouse
and human. We were interested in determining which of these
related genes can metabolize TMA to TMAO. All five members
of the family (human orthologs) were cloned into expression
constructs, in either untagged form or tagged with the FLAG
sequence at the N terminus, and transfected into the human
kidney cell line HEK293AD together with a plasmid express-
ing green fluorescent protein (GFP). As controls, cells were
transfected with pcDNA (empty) or pcDNA-expressing b-galac-
tosidase. We did not detect any significant differences in
transfection efficiency (as determined by GFP expression)
(Figure 1A; see Figure S1A online). Nonetheless, the relative
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vidual FMO orthologs varied significantly (Figure 1B, Figures
S1B–S1E). Western blot assays utilizing antibody to the FLAG
epitope demonstrated similar protein levels of FMO1, FMO3,
and FMO5 in transfected cells, whereas the protein levels of
FMO4 and FMO2 were relatively low (Figure 1A). The low level
of FLAG-tagged FMO2 protein relative to FMO1 and FMO3
was surprising, as the mRNA levels for all three FMOs were
similar (Figure 1B, Figures S1B and S1C), suggesting that
FMO2 might be regulated by posttranslational mechanisms.
We then determined the ability of the different FMOs (tagged
and untagged) to metabolize TMA into TMAO by adding deuter-
ated TMA (d9-TMA) to the transfected cells for 24 hr before
collecting the media and measuring the levels of deuterated
(d9)-TMAO by HPLC with online tandem mass spectrometry
(see the Experimental Procedures) (Figures 1C and D). Of the
five FMOs, only FMO1 and FMO3 exhibited the ability to sig-
nificantly oxidize TMA to TMAO, although very low levels of
TMAO were detected in the media of cells transfected with the
FMO2 plasmid (Figure 1C). FMO3 was by far the most active
FMO family member able to synthesize TMAO (Figure 1C), and
the activity was reflected by a reduction in the levels of the
substrate TMA (Figure 1D). Further, the 15-fold higher levels of
TMAO production by FMO3 as compared to FMO1 (Figure 1C)
were observed despite similar cellular levels of both FLAG-
tagged proteins (Figure 1A). In addition, comparison of the
enzymatic activities of FLAG-tagged with untagged constructs
of FMO1 and FMO3 suggests that the FLAG epitope does not
affect enzyme activity (Figure 1C). Finally, western blot assays
using a specific antibody against FMO3 showed that tagged
and untagged FMO3 protein levels were similar (Figure 1A).
Based on these data, we determined the relative specific acti-
vities of FMO1-FMO5 in transfected cells by dividing the levels
of TMAO present in the medium by the cellular FMO protein
(determined by densitometry of FLAG tagged protein). On this
basis, the specific enzymatic activity of FMO3 is approximately
10-fold higher than FMO1 (Figure 1E). The very low activity and
protein levels of FMO2 precluded accurate determination of
a specific activity. These data, taken together, suggest that
human FMO3 is likely the major enzyme capable of synthesizing
TMAO from TMA. Consequently, we focus our efforts on the
investigation of FMO3.
We first determined which tissues expressed FMO3, and
among the various mouse tissues we examined, FMO3 mRNA
levels were highest in the livers of female mice (Figure 1F).
FMO3 mRNA levels were lower (approximately 100-fold) in the
livers of male mice (Figure 1F). Adrenal FMO3 expression also
exhibited a sexually dimorphic pattern (Figure 1F). In contrast,
male and female mice expressed similar levels of FMO3 in the
aorta and lung (Figure 1F). Thus, the sexual dimorphism that
results in significant differences in tissue expression of FMO3
is limited to the liver and adrenals.
The data described above from overexpression studies
indicate that the rank order of enzymatic activity is FMO3 >
FMO1[FMO2. To determine the relative hepatic expression
of these three genes in vivo, we analyzed RNA-Seq data ob-
tained from male and female C57BL/6J mice. The data show
that in females, hepatic FMO1 and FMO3 mRNA levels are ex-
pressed at similar levels, and FMO2 is expressed at lower levelsC(Figure 1G). All three FMO mRNAs were expressed at lower
levels in the livers of male mice compared to female mice
(Figure 1G).
We also determined whether the sexual dimorphic difference
was maintained in human liver. We first analyzed expression
data from 317 Caucasian human subjects and observed a sig-
nificant difference in FMO1 and FMO3, but not FMO2, expres-
sion betweenmales and females (Figure 1H, Figure S1F) (Schadt
et al., 2008). We also confirmed these differences by RT-qPCR
in a random subset of subjects from the Genebank cohort
(Bhattacharyya et al., 2008) (Figure 1I).
Together, these results suggest that FMO3 in both humans
and mice is the most active FMO family member able to synthe-
size TMAO from TMA, is highly expressed in liver, and exhibits
sexual dimorphism. Based on these findings, we conclude that
FMO3 contributes R90% of the total hepatic activity involving
oxidation of TMA to TMAO.
FMO3 Expression Contributes to Circulating
TMAO Levels
Having established that FMO3 can convert TMA to TMAO
in vitro, we next sought to determine whether modulation of
FMO3 levels in vivo would alter circulating plasma TMAO levels.
Given that FMO3 is highly expressed in liver of female mice, but
much lower in males, we carried out gain-of-function studies in
males and loss-of-function experiments in female mice. First,
we generated an adenovirus to overexpress mouse FMO3 in
the liver. Seven days after adenovirus injection into male mice,
FMO3 mRNA levels were overexpressed by 60-fold relative to
basal levels in males (Figure 2A), and this increase was accom-
panied by a large increase in FMO3 protein (Figure 2B), which
was only detectable in mice infected with the FMO3 adenovirus.
Importantly, this was associated with a modest but significant
increase in plasma TMAO levels (Figure 2C). These results
demonstrated that increased expression of FMO3 in the liver
increases circulating plasma TMAO levels. However, we also
noted that the fold increase in FMO3 mRNA and protein was
far greater than the corresponding change in plasma TMAO,
suggesting that additional mechanisms are involved in the
regulation of plasma TMAO levels. To determine the effect of
persistent hepatic overexpression of FMO3 in vivo, we gener-
ated FMO3 transgenic mice by overexpressing human FMO3
from a liver-specific albumin promoter (see the Supplemental
Experimental Procedures). Three founders carrying the trans-
gene were identified, and all exhibited moderate overexpres-
sion of both FMO3 mRNA and protein (data not shown). We
selected males from the line with the highest FMO3 expression
for further study (Figures S2A and S2B). The transgenic mice
and wild-type littermate controls were given drinking water
supplemented with choline (1.3%), the precursor of TMA. After
7 days the plasma TMAO levels were significantly higher in
FMO3 transgenic mice as compared to littermate controls
(Figure 2C). Similar effects were observed in the other FMO3
transgenic lines (data not shown).
To examine the effects of reduced FMO3 expression, we
utilized a specific FMO3 antisense oligonucleotide (ASO).
Treatment of female mice with the ASO resulted in more than
90% reduction in liver FMO3 mRNA levels (Figure 2D) as well






Figure 2. Modulation of Hepatic FMO3
Levels in Mice Regulates Plasma TMAO
Levels
(A–C) FMO3 overexpression in the livers of male
C57BL/6 mice infected with either Ad-control or
Ad-FMO3 for 7 days (n = 8 mice/group). (D–F)
FMO3 knockdown in livers of female C57BL/6
mice treated with either vehicle (saline) or FMO3
antisense oligonucleotide (ASO) once weekly
(50 mg/kg body weight) for 7 weeks (n = 4 mice/
group). (A and D) Hepatic FMO3 mRNA levels
determined by RT-qPCR and normalized to 36B4
or cyclophilin levels. (B and E) Hepatic FMO3
protein levels determined by western blotting
analysis normalized to b-actin levels. (C and E)
Plasma TMAO levels determined from plasma
isolated from adenovirus-treated or ASO- or
vehicle-treated mice. TMAO levels were deter-
mined by LC/MS/MS. Data are presented as
mean ± SEM. Significance was measured with
Student’s t test. *p < 0.05, **p < 0.01, and ***p <
0.001.
Cell Metabolism
Genetic and Dietary Regulation of TMAOresulted in a 47% decrease in plasma TMAO levels (Figure 2F)
and a more than 2-fold increase in plasma TMA levels in FMO3
ASO-treated mice relative to vehicle-treated controls (Fig-
ure S2D). ASO treatment did not result in abnormal plasma
ALT and AST levels, indicating normal liver function, although
there was a small but statistically significant increase in ALT
levels in ASO-treated mice (Figure S2E).
Based on these results, we conclude that FMO3 is the rate-
limiting enzyme in the conversion of TMA to TMAO. Increased
hepatic expression of FMO3 protein in vivo results in decreased
TMA and increased plasma TMAO, whereas decreased expres-
sion of FMO3 has the reciprocal effect. It is also clear that the
change in FMO3 mRNA and protein is not necessarily reflected
in TMAO levels, indicating that posttranscriptional events and/
or alternative mechanisms are likely involved in regulating
plasma TMAO levels.
Dietary and Sex-Biased Regulation of FMO3 and TMAO
As shown above (Figures 1F and 1G), mice exhibit dramatic sex-
specific differences in hepatic FMO3 expression. To investigate
this further, we examined the effects of choline-enriched diet
on hepatic FMO3 gene expression, enzymatic activity, and
plasma TMAand TMAO levels inmale and femalemice (Figure 3).
Supplementation of the control diet with choline (1%), which
greatly increases TMA production by the gut flora (Zeisel
et al., 1989), did not affect the expression of hepatic FMO3
in either female or male mice (Figure 3A). However, compared
to a chow diet, choline supplementation in both males and
females resulted in a very large increase in plasma TMAO levels
(Figure 3B). The increase in plasma TMAO levels was more
pronounced in females than in males (Figure 3B), consistent
with higher hepatic FMO3 expression in female mice.
Conversely, the levels of the precursor metabolite TMA were
much higher in male than female mice fed the choline-enriched52 Cell Metabolism 17, 49–60, January 8, 2013 ª2013 Elsevier Inc.diet (Figure 3C). The observation that
males had higher levels of TMA is consis-
tent with a reduced capacity to synthe-size TMAO in the presence of presumably a large excess of
the substrate TMA derived from dietary choline. These changes
were not due to altered FMO activity, as the ability of liver
homogenates to oxidize TMA to TMAO was independent of the
diet (Figure 3D), although the expected differences existed
between males and females.
Gender differences in plasma TMAO levels could also be
caused by altered fractional excretion of TMAO. In female
mice, we found no significant differences in fractional excretion
rates of TMAO between mice fed either a choline-rich or control
diet in females (Figure S3A). In contrast, males had a small
but statistically significant increased fractional excretion rate
compared to females fed the same control diet (Figure S3A),
but these results are unlikely to explain the observed differences
in TMAO levels. To investigate possible differences in gut flora
between genders, we isolated microflora from different regions
of the intestine from male and female mice and measured
their ability to convert cholinetrimethyl-d9 (d9-choline) to trime-
thylamine-d9 (d9-TMA). The levels of activity were higher in the
cecum compared to the jejunum, but no significant differences
were observed between males and females (Figure S3B).
Together, these results suggest that the differences in circulating
TMAO levels in male and female mice are not due to differences
in aerobic intestinal bacterial flora.
To determine if the gender effects present in mice were also
observed in humans, we examined plasma TMAO levels in
random samples from patients from the Genebank cohort.
Surprisingly, we were unable to detect any difference in circu-
lating TMAO levels (Figure S3C). Similar to our studies in mice,
we did not observe any difference in the fractional excretion
rate of TMAO in a separate cohort of 20 male and female
subjects (Figure S3D).
These collective observations, although consistent with a rate-
limiting effect of FMO3 on the conversion of TMA to TMAO,
A C
B D
Figure 3. Sex and Dietary Choline Regulate
Hepatic FMO3 Expression and Plasma
TMAO Levels in Mice
(A–D) Male and female ApoE/ mice were fed
either a control (chow) or a choline-rich diet (1%
choline) (n = 7–10 mice/group). (A) Hepatic Fmo3
mRNA levels determined by RT-qPCR and
normalized to 36B4 expression. (B) Plasma TMAO
and (C) TMA levels from male and female mice
determined by LC/MS/MS. (D) Conversion of
TMA into TMAO by liver homogenates (FMO
activity) of male and female mice normalized
to total hepatic protein levels. Data are presented
as mean ± SEM. Significance was measured with
one-way ANOVA, and different letters (a–d) indi-
cate statistically significant (p < 0.05 or greater)
differences between groups.
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synthesis of TMAO. This may be particularly relevant for diets
rich in choline-containing products. Thus, any sex-related differ-
ences in plasma TMAO levels may have been obscured as
a result of varied diets across the human population.
Hormonal Regulation Underlying Sexual Dimorphism
of FMO3 Expression and TMAO Levels
To investigate the mechanism underlying the observed gender
differences, we examined the effects of testicular and ovarian
hormones on hepatic Fmo3 gene expression. First, we utilized
either intact or gonadectomized (GDX) C57BL/6J male mice
either treated with dihydrotestosterone (DHT) or placebo.
Conversely, we also compared intact and ovariectomized (OVX)
C57BL/6 femalemice treatedwith either estradiol (E2) or placebo
(Figure 4). Compared to intact male mice, GDX-males exhibited
a more than 100-fold increase in hepatic Fmo3mRNA levels, as
well as increased FMO3 protein and a 7-fold increase in plasma
TMAO (Figures 4A–4C). Treatment of the GDX males with DHT
caused a profound decrease (90%) in FMO3 mRNA, protein,
and plasma TMAO (Figures 4A–4C). Together, these data
suggest that the low hepatic expression of FMO3 is at least partly
a result of repression by androgens/dihydrotestosterone. In
females, ovariectomy caused a modest decrease in hepatic
FMO3 expression, protein, and plasma TMAO levels (Figures
4A–4C). Interestingly, treatment of OVX femaleswith estrogen re-
sulted in a small but significant increase in hepatic FMO3 mRNA
and protein and in plasma TMAO levels (Figures 4A–4C).
In addition to acute hormonal effects, sex differences can
also result from differences in development and the sex chro-
mosomes. We assessed such potential by profiling livers from
the ‘‘four core genotype’’ mice, consisting of XX females, XX
males, XY females, and XY males. These were generated using
deletion (XY females) or transgenic expression (XX males) of
the testes factor-determining gene (Arnold and Burgoyne,
2004). To eliminate the acute effects of sex hormones, the
mice were gonadectomized at 10 weeks of age. We could not
detect any differences in FMO3 gene expression among theCell Metabolism 17, 49–FCG strains (Figure S4), indicating that
the effects of gender on FMO3 expres-
sion are due entirely to hormonal effectsrather than permanent alterations to FMO3 during development.
Taken together, these results indicate that testosterone is
largely responsible for the reduced hepatic FMO3 expression
observed in males, and the estrogen-dependent induction of
FMO3 expression may further exacerbate the gender differ-
ences. The concordant increase in hepatic FMO3 and plasma
TMAO in GDX males is consistent with the rate-limiting role of
FMO3 in TMA oxidation.
Regulation of FMO3 by FXR
In preliminary studies of mice carrying a transgene for the human
ApoB100 gene (hApoB100), we noted that a high-fat, choles-
terol-containing diet (HF) supplemented with the bile acid cholic
acid (HF+CA) resulted in increased atherosclerosis and hepatic
FMO3 expression, as compared to mice fed the HF diet. To
investigate whether the increase in FMO3 levels was specifically
due to the presence of dietary cholic acid, we fed five inbred
strains that carry the hApoB100 transgene either the HF or
HF+CA diet and determined FMO3 expression and plasma
TMAO levels. As shown in Figures 5A–5D, hepatic FMO3
mRNA and circulating plasma TMAO levels were increased in
the presence of dietary cholic acid, suggesting bile acids regu-
late FMO3 activity in both male and female mice.
Many effects of bile acids on gene expression are mediated
via activation of the nuclear hormone receptor farnesoid X
receptor (FXR, Nr1h4). To investigate whether FXR could
regulate Fmo3 gene expression and TMAO levels in vivo, we
utilized a combination of loss- and gain-of function approaches.
Given that hepatic FMO3 expression was profoundly different
in males and females, we decided to treat both male and
female wild-type (C57BL/6) or Fxr/ mice for 3 days with either
vehicle or GSK2324, an FXR-specific agonist (Bass et al., 2011).
As a positive control we showed that GSK2324 treatment of
both male and female wild-type, but not Fxr/ mice, led to
induction of the well-characterized FXR target gene BSEP/
ABCB11 (Figure 6A). As expected, the basal expression levels
of Bsep and the fold induction after FXR activation were similar
for both male and female mice (Figure 6A). Induction of hepatic60, January 8, 2013 ª2013 Elsevier Inc. 53
AB
C
Figure 4. Gonadal Hormones Regulate Hepatic FMO3 Expression
and Plasma TMAO Levels
(A–C) Male and female C57BL/6 mice were either untreated or gonadecto-
mized or ovariectomized and then treated with vehicle or DHT (males) or
estrogen (females) (n = 4–6 mice/group). (A) Hepatic FMO3 expression was
determined by RT-qPCR and normalized to 36B4. (B) FMO3 protein levels
were determined by western blot analysis, and GAPDH was used as a control.
(C) Plasma TMAO levels from male and female mice were determined by LC/
MS/MS. Data are presented as mean ± SEM. Significance was measured
with one-way ANOVA, and different letters (a–e) indicate statistically significant
(p < 0.05 or greater) differences between groups.
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Fxr/-treated mice (Figure 6B). However, in contrast to BSEP,
the fold induction of FMO3 in the livers of wild-type males
was far greater than was observed in female mice (20-fold
versus 2.5-fold increase) (Figure 6B). Nonetheless, FXR acti-
vation with GSK2324 led to increased plasma TMAO levels in
wild-type male and female mice, but not Fxr/mice (Figure 6C).
These findings suggest that FMO3 might be a direct target of
activated FXR, resulting in increased conversion of TMA to
TMAO. The finding that basal FMO3 mRNA levels were similar
in wild-type and Fxr/ mice of the same gender (Figure 6B)
suggests that basal FMO3 mRNA levels are independent of
FXR but dependent upon gender.
To further characterize the induction of FMO3, we next utilized
an alternative FXR agonist (GW4064) together with wild-type
mice or mice that lack FXR in the liver (L-KO) or intestine
(I-KO). The studies demonstrated that GW4064 induced hepatic
FMO3 at least 17-fold in wild-type and I-KO mice but failed to
induce FMO3 mRNA levels in L-KO mice (Figures S5A–S5C).
Consequently, we conclude that induction of hepatic FMO3 is
dependent upon hepatic but not intestinal FXR. In addition,
FXR activation modestly induced hepatic FMO2 (2-fold) without
affecting FMO1 or FMO4 mRNA levels (Figures S5D–S5F). This
suggests some degree of coordinate regulation of FMO3
and FMO2 which physically reside at the same chromosome54 Cell Metabolism 17, 49–60, January 8, 2013 ª2013 Elsevier Inc.locus (Figures S6D–S6F). Taken together, these results demon-
strate coordinate regulation of FMO3 and plasma TMAO levels
by the FXR agonists GSK2324, GW4064, and cholic acid.
To identify the molecular mechanism involved in the induction
of FMO3 by FXR, we next utilized two independent ChIP-Seq
genome-wide surveys of FXR binding sites (Chong et al., 2010;
Thomas et al., 2010). We identified three FXR response ele-
ments (FXREs) near the Fmo3 gene locus, including one in the
promoter-proximal region 1.8 kb upstream of the transcriptional
start site (asterisk in Figure S6). To determine whether the FXRE
in the proximal promoter was functional, we generated an Fmo3
promoter-luciferase reporter plasmid and transfected it into
Hep3B cells, a human hepatoma cell line. FXR overexpression
and activation with the GSK2324 caused a dose-dependent
increase in FMO3 promoter-driven luciferase reporter activity
(Figure 6D). The FXR-dependent effect was completely abol-
ished when the FXRE in the Fmo3 promoter was mutated
(Figure 6D), indicating that FMO3 is a direct FXR target gene.
We also investigated possible regulation of FXR target genes
by the TMA-FMO3-TMAO pathway. Preliminary data obtained
after feeding male apoE/ mice normal chow or chow supple-
mented with either choline (1%) or TMAO (0.12%) suggest that
these diets do not significantly affect the expression of the FXR
target genes Shp and Bsep (data not shown).
Natural Variation Affecting FMO3 Regulation,
TMAO Levels, and Atherosclerosis
We surveyed two panels of inbred strains of mice to identify
common genetic factors contributing to FMO3 expression or
plasma TMAO levels. To identify genetic variants regulating
FMO3 levels, we queried a database containing expression
data for the Hybrid Mouse Diversity Panel (HMDP, http://
systems.genetics.ucla.edu/). This panel consists of about 100
inbred strains of mice that have been fully genotyped and
characterized for various clinical intermediate phenotypes such
as gene expression. This panel has unprecedented mapping
resolution and has sufficient power to map genes contributing
to 5% or more of the overall trait variance (Bennett et al., 2010;
Ghazalpour et al., 2012). FMO3 expression varied significantly
among the HMDP strains, and the major locus regulating ex-
pression mapped directly over the FMO3 gene, at 164 Mb on
chromosome 1, suggesting cis-acting regulation (Figure 7A,
red dots). This variation of FMO3 allowed us to examine the
relationship between FMO3 expression, TMAO levels, and
atherosclerosis. We therefore surveyed an additional panel of
22 strains of mice carrying a hyperlipidemia-inducing human
apolipoprotein B gene (Bennett et al., 2012). There was a clear
relationship between the variation of FMO3 expression and the
levels of plasma TMAO when both males and females were
examined (r = 0.57, p < 0.001) (Figure 7B). The strains were
previously typed for atherosclerosis susceptibility, with males
exhibiting much smaller lesions than females (Bennett et al.,
2012). We measured plasma TMAO levels in mice of each strain
(n = 3–8 mice/strain) (Figure 7C) and observed a significant
correlation between TMAO and atherosclerosis in females (r =
0.34, p < 5 3 105) (Figure 7D). Most of the males exhibited
few significant lesions, and the correlation with TMAO was not
significant (data not shown). We did not observe any differences




Figure 5. Dietary Cholic Acid Induces Fmo3
Expression and TMAO Levels in Common
Inbred Mouse Strains
Female (A and C) and male (B and D) ‘‘humanized’’
ApoB100 transgenic mice were fed a high-fat diet
with cholic acid (HF+CA) or without cholic acid
(HF) (n = 2–9 mice/strain/gender). (A and B)
Hepatic FMO3 expression was determined by
RT-qPCR normalized to 36B4 expression.
(C and D) Plasma TMAO levels from male and
female mice of different strains were determined
by LC/MS/MS. Data are presented as mean ±
SEM. Significance was measured with Student’s
t test. *p < 0.05, **p < 0.01, and ***p < 0.001.
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TMAOexplains about 11% (r2) of the total variation of atheroscle-
rosis among common inbred strains included in the panel.
Our studies have demonstrated that FMO3 expression is
genetically regulated and that FXR is a crucial regular of FMO3
levels. Thus, we next investigated if there are natural variations
localized near any of the FXREs identified by ChIP-Seq analysis
(Figure S6) and if these variations lead to differences in FXR-
mediated FMO3 transcription. We first cloned the 2.5 kb
promoter region of FMO3 from eight strains of mice into a lucif-
erase reporter plasmid and determined that FXR activation of
FMO3 was not affected by the genetic variation in the promoter
region (Figure S7). Our analysis identified one SNP that was
adjacent to an intronic FXRE that was associated with variation
of FMO3 expression at genome-wide significance levels (arrow
in Figure 7E). We then made luciferase reporter plasmids con-
taining three copies of the FXRE and flanking region containing
either SNP (A or G). FXR activation of the reporter plasmid was
significantly affected, with the FXRE containing the G SNP
having a much lower activity (Figure 7F). Taken together, these
results indicate that genetic variation of FMO3 expression is at
least partly mediated by the nuclear receptor FXR.
DISCUSSION
Wang and colleagues (Wang et al., 2011) recently reported
a striking relationship between the levels of TMAO and athero-
sclerosis in a large population of heart disease patients and
controls, and studies in mice were consistent with a causal
relationship. Understanding the factors that regulate circulating
levels of TMAO is therefore clearly important if pharmacologic
strategies are to be employed to modulate TMAO levels.
FMO3 was considered a strong candidate for the conversionCell Metabolism 17, 49–of TMA to TMAO, since a human disorder
characterized by elevated TMA levels
and resulting in a pungent odor, termed
fish malodor syndrome, had been shown
to be the result of FMO3 mutations
(Treacy et al., 1998). We have now
further investigated factors contributing
to TMAO metabolism in both humans
and mice. A number of conclusions
have emerged. First, three members of
the FMO family are shown to be capableof oxidizing TMA to TMAO, although FMO3 exhibits the highest
specific activity. Second, using overexpression and antisense-
mediated silencing in mice, FMO3 expression is shown to sig-
nificantly affect both TMA and TMAO levels. Third, FMO3
expression and TMAO levels in mice are shown to exhibit a
strong gender bias, and testosterone inhibition of FMO3 ex-
pression is shown to underlie the gender difference. Fifth, levels
of TMAO and FMO3 expression are regulated by the nuclear
receptor FXR. Finally, studies of natural genetic variations in
mice are consistent with a role of FMO3 in controlling TMAO
levels and a role of TMAO levels in atherosclerosis susceptibility.
Each of these points is discussed in turn below.
The FMO family (reviewed in Cashman and Zhang, 2006)
consists of five family members, FMO1–FMO5, and we ex-
pressed each human FMO in tissue culture cells and measured
the ability of lysates to convert TMA to TMAO. These studies
indicated that several members, FMO1, FMO2, and FMO3, ex-
hibited some level of activity. Using FLAG-tagged FMO expres-
sion plasmids, we show that FMO3 exhibited about a 10-fold
greater specific activity than FMO1. The specific role of FMO2
in regulating TMAO levels is confounded by the reduced protein
levels. Based on hepatic expression levels in mice and humans,
we concluded that FMO3 accounted for the majority of the
activity, with the exception of male mice, which exhibited very
low levels of FMO3. Since FMO1 expression is very high in the
male liver, and FMO1 has the ability to convert TMA to TMAO,
we speculate that FMO1 may be partly responsible for TMAO
synthesis in male mice. While the liver was the major site of
expression of the FMOs, it is noteworthy that the adrenals,
lung, and aorta also expressed substantial FMO3, raising the
possibility of extrahepatic conversion of TMA to TMAO.
In vivo loss- and gain-of-function experiments demonstrated
that FMO3 expression is a major regulator of TMAO levels.60, January 8, 2013 ª2013 Elsevier Inc. 55
AB D
C Figure 6. FMO3 Is an FXR Target Gene,
and FXR Activation Induces FMO3 and
Increases Circulating TMAO Levels In Vivo
(A and B) (A) Hepatic Bsep and (B) Fmo3 mRNA
levels normalized to 36B4 were determined in
male and female wild-type and Fxr/ mice
treated with GSK2324 at 30 mpk/day for 3 days
(n = 7–10 mice/group).
(C) Plasma TMAO levels from the same mice were
determined by LC/MS/MS.
(D) Luciferase reporter plasmids under the control
of either 2.5 kb of the wild-type mouse FMO3
promoter or the promoter containing a mutant
FXRE were transfected into Hep3B cells (six
wells per condition) in the presence of increasing
amounts of pcDNA FXRa2 and treated with vehicle
(water) or GSK2324 (1 mM). Promoter activity was
determined by luciferase assay and normalized
to b-galactosidase (cotransfected to account for
transfection efficiency). Data are presented as
mean ± SEM. Significance was measured with
Student’s t test. *p < 0.05, **p < 0.01, and ***p <
0.001.
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are generally far greater than the corresponding changes in
circulating TMAO levels. This is particularly true in male mice.
This discrepancy is consistent with other factors contributing
to TMAO synthesis. This may include FMO1 and possibly
FMO2, or posttranscriptional modifications of FMO3 that
enhance activity. This warrants further investigation and may
represent a pathway that can be targeted pharmacologically.
Since loss of FMO3 expression causes fish malodor syndrome,
it would not be a straightforward pathway to target in order to
reduce TMAO levels. However, if activity can be modulated,
perhaps the undesirable effect of TMA accumulation can be
diminished or avoided.
We also investigated themolecular mechanisms for the effects
of both gender and bile acids on the expression of FMO3 and
TMAO levels. Inmice, females hadmuch greater hepatic expres-
sion and protein levels of FMO3 as compared to males, and the
difference was approximately 100-fold in most strains of mice.
Whereas females exhibited higher levels of plasma TMAO than
males, the reverse was true of TMA levels, indicating that female
mice exhibit more efficient conversion of TMA to TMAO. Since
hepatic FMO3 levels are also elevated in females, and correlate
significantly with plasma TMAO levels, it appears that FMO3 is
the primary cause for differences in TMAO levels between
male and female mice. In humans, males also exhibited reduced
levels of FMO3 expression as compared to females, although the
differences were much more modest. However, in contrast to
mice, there were no discernible differences in circulating
TMAO levels between genders in a human population. We attri-
bute these differences to the varied diet consumed by humans.56 Cell Metabolism 17, 49–60, January 8, 2013 ª2013 Elsevier Inc.Given that FMO3 and TMAO levels are
largely affected by diet, any differences
in TMAO between sexes would likely be
obscured. In addition, our studies with
GDX- or OVX-treated mice indicate that
differences in FMO3 expression andTMAO levels also appear to be under strong hormonal control.
This notion is supported by human studies in which it has
been reported that menstruation can induce transient trimethy-
laminuria (high levels of TMA in urine) (Shimizu et al., 2007)
and that plasma TMAO levels are reduced in menopausal
women (Spencer et al., 2012). This latter observation is consis-
tent with our findings in mice that estrogen promotes hepatic
FMO3 expression. The reason for these striking differences in
mice, as compared to the modest differences in humans, is
unknown, but may relate to the processing of pheromones that
affect sexual behaviors. Pheromones are important cues in
mating in mice (reviewed in Touhara and Vosshall, 2009), and
FMO3 could affect the oxidation of some of these pheromones.
Alternatively, TMA or TMAO could have pheromone-like effects.
Conceivably, the elevated levels of TMA during menstruation
could act as a sexual deterrent.
We have examined the effects of various diets on TMAO
metabolism in mice, and observed that diets containing cholic
acid induced hepatic FMO3mRNA and protein as well as plasma
TMAO levels. Dietary supplementation with cholic acid has long
been known to promote atherosclerosis (Paigen et al., 1987). Our
current studies suggest for the first time that this increase in
atherosclerosis may be due in part to the activation of FXR and
the subsequent elevation of FMO3 and synthesis of TMAO, in
addition to the effect of bile acids on lipoprotein levels. These
conclusions are based on the observations that cholic acid
induction of FMO3 was mediated by the bile acid-activated
nuclear receptor FXR, that FMO3 is a bona fide FXR target
gene, and that activation of FXR in vivo is accompanied by an






Figure 7. Natural Genetic Variation of Hepatic
FMO3, Plasma TMAO Levels, and Atheroscle-
rosis among Common Inbred Strains of Mice
(A) Identification of a cis-acting expression quantitative
trait locus (eQTL) for FMO3 among the 100 HMDP
strains of mice. Approximately 135,000 SNPs varying
across the HMDP panel were examined for association
with FMO3 transcript levels following correction for
population structure (see the Experimental Proce-
dures). The location of each SNP across the 19 auto-
somes and the X chromosome is indicated on the
x axis, and the strength of association is shown on the
y axis. Signals shown in red indicate genome-wide
significant results.
(B) Relationship between hepatic FMO3 transcript
levels and circulating TMAO levels in 22 strains (males
and females) carrying the human ApoB transgene fed
a western diet.
(C) TMAO levels in female mice of the 22 hyperlipidemic
strains on a western diet.
(D) Relationship between atherosclerotic lesions and
TMAO levels in female mice of the 22 hyperlipidemic
strains (points represent single animals). Atheroscle-
rotic lesions were quantitated following the sectioning
of the aortic sinus and proximal aorta.
(E) A high-resolution image of (A) showing that the
peak SNPs reside over the location of the FMO3 gene
on chromosome 1.
(F) Three copies of the DNA region containing the A or
G SNP adjacent to the intergenic FXRE were cloned
into a minimal TK promoter luciferase reporter plasmid.
SNP reporter plasmids were transfected into Hep3B
cells (six wells/condition) with increasing amounts of
pcDNA FXRa2 and treated with vehicle (water) or
GSK2324 (1 mM). Promoter activity was determined
by luciferase assay and normalized to b-galactosidase
(cotransfected to account for transfection efficiency).
Data are presented as mean ± SEM.
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and phase III xenobiotic genes (Lee et al., 2010), and the various
FMO genes are also thought to function as phase I xenobiotic
genes (Krueger and Williams, 2005). The regulation of FMO3
by FXR provides a potential target for therapeutic modulation
of TMAO levels, although the broad metabolic effects of FXR,
including the relationship with hepatic lipoprotein and bile acid
metabolism, may restrict such therapeutic applications. FXR
activation has been shown to protect mice from atherosclerosis
(Hartman et al., 2009). Nonetheless, the induced FMO3 and
TMAO levels would raise some concerns about the use of FXR
agonists as therapeutic agents. Our data also reveal a mecha-
nism for the complex relationship between FXR and atheroscle-
rosis, and the disparate atherosclerosis results observed in
several FXR knockout studies (Hageman et al., 2010; Zhang
et al., 2006). Given that the precise functions of TMAO remain
to be identified, it will be important to determine what role
TMAO plays following FXR activation.
Our studies have focused on total transcript and protein levels
of FMO genes, but additional mechanisms of regulation, such as
alternative splicing and post-transcriptional regulation could
account for differences between transcriptional activation and
FMO activity. Previous reports (Lattard et al., 2004) and recent
data from the 1000 genomes project (Altshuler et al., 2010)
have identified multiple splice variants for the human FMO1,CFMO2, and FMO3 genes. In the case of FMO3, there are nine
splice variants, of which four are protein coding and five are
processed transcripts. At least two of these splice variants affect
the catalytic activity of human FMO1 and FMO3 (Lattard et al.,
2004) and may indicate an important factor affecting TMAO
production. In addition to isoform variation, there is some
evidence that nitric oxide reduces FMO1 mRNA stability and
FMO3 activity through a posttranscriptional modification (Ryu
et al., 2004a, 2004b). Further study is necessary to determine
the functional impact of individual FMO isoforms and possible
posttranscriptional modifications on TMA oxidation and, ulti-
mately, cardiovascular risk.
A long-term goal of our work is to understand the natural
variations of TMAO metabolism in human populations. We
have performed limited genome-wide association studies of
human populations and, thus far, these have not been informa-
tive in terms of identifying loci controlling TMAO levels (our
unpublished data). This may be related to the large perturbations
in TMAO levels resulting from dietary differences. It may also be
attributable to the fact that intestinal microflora, more so than
a somatic genetic factor, play a more prominent role in variation
of TMAO levels. Although the specific genetic variations con-
tributing to TMAO levels in human populations are unlikely to
be the same as those that occur in mouse populations, the
pathways are likely to be shared, at least in part. Therefore, weell Metabolism 17, 49–60, January 8, 2013 ª2013 Elsevier Inc. 57
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panels of mouse strains, one on a hyperlipidemic genetic
background. We found that there was considerable variation in
FMO3 expression among strains and that the FMO3 variations
influenced TMAO levels, consistent with our targeted studies.
Overall, TMAO levels explained about 11% of the differences
in atherosclerosis susceptibility in females in the 22 strains
investigated, roughly consistent with human population studies
(Wang et al., 2011). Preliminary studies by Wang et al. (Wang
et al., 2011) suggested that TMAO levels increase the formation
of cholesterol-engorged macrophages and that this might
occur through upregulation of scavenger receptors for modified
lipoproteins. Our results, particularly those indicating a role of
bile acids in TMAO levels, further hint that the mechanism(s)
by which TMAO affects atherosclerosis may involve lipids. Our
studies in mice also clearly indicate that FMO3 only partly
explains the variations in plasma TMAO levels. Other likely
factors include other enzymes that can metabolize TMA to
TMAO, including FMO1, or perhaps FMO2, and most promi-
nently, gut flora composition. Numerous reports in the literature
have shown that there is genetic control of the composition of
gut flora (Benson et al., 2010; Dumas et al., 2006; Kovacs
et al., 2011; Turnbaugh et al., 2010). However, to date we are
unaware of any direct evidence linking alterations in one micro-
bial population affecting TMAO levels in humans ormice. Gender
differences in TMAO levels in mice were not due to differences
in the production of TMAO in cultures of gut flora between
sexes of mice. These studies were specific to aerobic species,
and we cannot rule out the possibility that there were differences
from anaerobic bacteria.
In conclusion, our study extends our previous findings (Wang
et al., 2011) and supports a causal relationship between FMO3
expression, TMAO levels, and atherosclerosis. Clearly, the rela-
tionship is affected by gender (at least in mice) and dietary
factors. The identification of a regulatory factor(s) affecting
TMAO levels provides a possible target(s) for therapeutic inter-
vention in fish malodor syndrome and atherosclerosis.
EXPERIMENTAL PROCEDURES
Mice, Diets, and Treatments
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). All mice were maintained on a 12 hr light-dark cycle and fed a standard
chow diet (NIH31 modified mouse/rat diet, catalog number 7013, Harlan
Teklad) ad libitum. For gonadectomy/ovariectomy experiments, C57BL6/J
were gonadectomized at 8 weeks of age, implanted with hormone pellets
at 12 weeks, and killed at 14 weeks. Male and female mice of the hormone-
treated groups received subcutaneous implants of either 0.5 mg estradiol
pellet or a 5 mg dihydrotestosterone pellet to release over 21 days. Control
mice were treated with the placebo pellet (Innovative Research of America;
placebo, catalog item number C-111). For FMO3 ASO studies, four 6- to
8-week-old female C57BL/6 mice per group, on chow diet, received seven
once-weekly intraperitoneal injections of saline or the Fmo3 ASO at a dose
of 50 mg/kg body weight. Mice were euthanized and plasma and liver tissue
collected. For atherosclerosis studies, ApoB-100 Tg mice were purchased
from Taconic and bred with 13 inbred strains purchased from the Jackson
Labs as previously described (Bennett et al., 2012). The mice were fed Purina
Chow containing 4% fat until 8 weeks of age and then transferred to a high-fat
diet (37% fat) containing cholesterol (1.25%) and cholic acid (0.5%), Harland
Teklad TD.88051. A subset of mice were placed on high-fat, cholesterol-
containing diet but without cholic acid (Teklad Western TD.88137). For FXR
studies, male or female 10- to 12-week-old mice wild-type and Fxr/ mice58 Cell Metabolism 17, 49–60, January 8, 2013 ª2013 Elsevier Inc.(backcrossed to C57BL/6J mice for ten generations at UCLA) were treated
with either vehicle (water) or GSK2324 (Bass et al., 2011) at 30 mpk, once
a day for 3 days. All animal experiments were approved by the Office of
Animal Research Oversight (OARO) at UCLA.
Quantification of TMAO, TMA, and Creatinine
Quantification of TMAO and TMA in mouse plasma was performed using
stable isotope dilution HPLC with online electrospray ionization tandem
mass spectrometry on an API 365 triple quadrupole mass spectrometer
(Applied Biosystems, Foster, CA) with upgraded source (Ionics, Bolton, ON,
Canada) interfacedwith a Cohesive HPLC (Franklin, MA) equipped with phenyl
column (4.6 3 2,505 mm, 5 mm Rexchrom Phenyl; Regis, Morton Grove, IL),
and the separation was performed as reported previously (Wang et al.,
2011). TMAO and TMA were monitored in positive MRM MS mode using
characteristic precursor-product ion transitions: m/z 76 /58, m/z 60/44,
and m/z 114/86, respectively. The internal standards TMAO-trimethyl-d9
(d9-TMAO) and TMA-d9 (d9-TMA) were added to plasma samples before
sample processing and were similarly monitored in MRM mode at m/z
85/68, m/z 69/49, and m/z 117/89. Various concentrations of TMAO
and TMA standards and a fixed amount of internal standards were spiked
into control plasma to prepare the calibration curves for quantification
of plasma TMAO and TMA. For d9-TMA and d9-TMAO quantification in
FMO activity analyses, 1,1,2,2-d4 choline (Sigma) was used as an internal
standard followed by a 0.5 ml 3K cutoff centrifugal filter (Millipore) of sample
prior to LC/MS/MS analysis. The characteristic precursor-product ion
transition for 1,1,2,2-d4 choline is m/z 108/60 monitored in positive
MRM MS mode.
FMO3 Antisense Oligonucleotide
A chimeric 20-mer phosphorothioate oligonucleotide targeted to mouse Fmo3
(50-TGGAAGCATTTGCCTTTAAA-30) containing 20-O methoxyethyl (MOE)
groups at positions 1–5 and 15–20 was synthesized and purified as described
(Baker et al., 1997) with an automated DNA synthesizer (380B, Perkin-Elmer-
Applied Biosystems, Foster City, CA). Plasma TMAO and TMA levels were
determined using LC/MS. Liver RNA was isolated and examined for the
expression of FMO3 mRNA by the Taqman probe based gene expression
analysis, and liver was also homogenized to determine FMOs activity.
Human Studies
Plasma TMAO levels were determined from sequential consenting subjects
seen in the cardiology clinic, at the Cleveland Clinic, and enrolled in the
GeneBank study. Details about this cohort have been previously described
(Bhattacharyya et al., 2008; Wang et al., 2011). Liver tissue from humans
came from residual liver biopsy material collected at the time of diagnostic
evaluation during surgery. All subjects gave informed consent, and all studies
were approved by the Cleveland Clinic Institutional Review Board. Microarray
data from human liver samples were downloaded from GEO (GSE9588),
inverse log10 transformed, and expressed as a fold difference between
males and females.
FMO1–FMO5 Plasmid Construction
Human FMO1–FMO5 cDNAs were cloned from cDNA generated from total
RNA derived from Hep3B or HepG2 cell lines (ATCC). Each cDNA sequence
was amplified by PCR using specific primers containing a Kozak site upstream
of the ATG and cloned into pcDNA3.1 plasmid (Life Technologies). For
FLAG-tagged plasmid construction, cDNA sequences for FMO1–FMO5
were reamplified using the primers containing Gateway att sequences (Life
Technologies), without the ATG start codon, and cloned into pDONR221
plasmid (Life Technologies). DONR plasmids were recombined into a
Gateway-adapted pcDNA3.1 plasmid containing an N-terminal FLAG
sequence using LR clonase (Life Technologies) according to the manufac-
turer’s instructions.
Cell Culture
HEK293Ad cells (Agilent) or Hep3B (ATCC) cell lines were cultured according
to ATCC recommendations. For FMO1–FMO5 activity assays, HEK293Ad
cells were seeded in 6- or 12-well plates at 70%–80% confluence.
Cells were transfected with 900 ng/well (6-well) or 450 ng/well (12-well plates)
Cell Metabolism
Genetic and Dietary Regulation of TMAOof pcDNA FMO1–FMO5, pcDNA N-FLAG FMO1–FMO5, pcDNA3.1, and
pcDNA3.1 LacZ plasmids. To determine transfection efficiency, cells were co-
transfected with pSicoR GFP plasmid (100 ng/well for 6-well or 50 ng/well for
12-well plates). Transfection was carried out after cells were washed and
placed in OPTI-MEM, using Fugene HD (Promega) as the transfection reagent
according to the manufacturer’s instructions. For Fmo3 promoter studies, the
3 kb region upstream of the mouse Fmo3 gene was cloned into pGL4.10
plasmid (Promega). Hep3B cells were seeded 24 hr prior to transfection in
48-well dishes. The following day, cells were transfected with FMO3 reporter
constructs and increasing concentrations of pcDNA3.1 FXRa2 expression
plasmid for 24 hr in OPTI-MEM using Fugene HD (Roche). Transfection
medium was removed and cells were treated with either vehicle (water) or
GSK2324 (1 mM) in medium containing 10% charcoal-inactivated serum
(Omega) for a further 24 hr before being harvested. Luciferase activity was
determined using Luciferase Assay System (Promega) and normalized to
b-gal activity to correct for variations in transfection.
Determination of Enzymatic Activity of Flavin Mono-oxygenases
For cell culture studies, HEK293Ad cells transfected with FMO1–FMO5 were
treated 24 hr posttransfection with 100 mM d9-TMA, and media was collected
and snap frozen in liquid nitrogen. Deuterated TMAO and TMA levels were
determined as described above.
Determination of enzymatic activity of hepatic FMOs was conducted in
250 ml reaction mix containing 1 mg liver protein homogenate, 100 mM d9-
TMA, and 100 mM reduced nicotinamide adeninedinucleotide phos-
phate (NADPH) in 10 mM HEPES (pH 7.4). Reaction was stopped 8 hr
later with 0.2 N formic acid, followed by filtering through a 3 K cutoff spin
filter, and then snap frozen and stored at 80C until time of analysis.
For analyses, internal standard was added to the thawed filtrate, which
was then injected onto an HPLC column with online tandem mass spec-
trometer to measure the oxidized product d9-TMAO as described above.
Control studies performed omitting NADPH did not show conversion of
TMA into TMAO.
Adenovirus Preparation
Mouse Fmo3 cDNA was amplified from cDNA synthesized from female
liver C57BL/6 total RNA and cloned into pAdTrack CMV plasmid. Control
adenovirus was made from an empty pAdTrack CMV plasmid. AdTrack or
AdTrack Fmo3 was recombined into pAdeasy plasmid in BJ5183 cells
(Agilent), and adenovirus particles were prepared using the AdEasy system
(Agilent). High-titer adenovirus particles were purified by CsCl gradient cen-
trifugation and dialyzed for 48 hr and stored at 80C. Particles were
quantified by serial dilution methods and detection of GFP-positive plaques
in HEK293Ad cells (Agilent). For in vivo overexpression, 109 plaque-forming
units (PFUs) were injected into the tail vein of 10- to 12-week-old male
C57BL/6 mice. Livers and plasma were collected 7 days postinfection after
a 4–5 hr fast.
Real-Time PCR
Total RNA was isolated in QIAZOL using the RNeasy Kit (QIAGEN) according
to the manufacturer’s instructions. Gene expression was determined from
cDNA synthesized using Reagents for Taqman kit (Applied Biosystems) from
500 ng of total RNA and using a Lightcycler 480 Real-time qPCR machine
and Lightcycler 480 Mastermix (KapaBiosystems). Relative gene expression
was determined using an efficiency corrected method, and efficiency was
determined from a 3-log serial dilutions standard curve made from cDNA
pooled from all samples. Primers were designed across exon-exon bound-
aries using Roche UPL guidelines. Results were normalized to Tbp, 36B4, or
b-actin mRNA.
RNA-Seq Experiments
Liver poly(A) mRNA was isolated from (DBA2J x C57BL) F1 mice, and libraries
were prepared as recommended by the manufacturer (Illumina, Hayward, CA,
USA). The samples were sequenced using the Illumina GAIIX sequencer to
a coverage of approximately 40 million single end reads of 75 bp. These
were aligned to the mouse reference genome mm9 allowing for up to five
mismatches as described (Trapnell et al., 2009).CWestern Blot Analyses
Whole-liver lysates were homogenized, or cell lysates were scrapped in RIPA
buffer (13 PBS with 1% SDS, 5g/L sodium deoxycholate, 1% NP-40) supple-
mented with protease inhibitor cocktail (Roche) fortified with additional
PMSF, leupeptin, aprotinin, and ALLN (Sigma) and quantified using the BCA
assay (Pierce). Equal amounts of protein (30 mg for male mice and 10 mg for
female mice) were separated on 4%–12% acrylamide gels (Bio-Rad) and
transferred to a PVDF membrane (Millipore). Membranes were blocked for
16 hr in 5% nonfat milk solution in Tris-buffered saline containing 0.5% Tween
20 and probed with antibodies to FMO3 (ABCAM, Ab126790), mouse mono-
clonal b-Actin (Sigma), GAPDH (Genetex), or FLAG (Sigma catalog number
F1804) for 1–3 hr. HRP detection was carried out using ECL plus reagent
(GE Healthcare) according to the manufacturer’s instructions. Densitometric
analysis was carried out using Quantity One software (Bio-Rad).
Statistical Analysis
Statistical analysis was performed using Prism Graphpad software (V5.0) or
Microsoft Excel. Comparison between control and treatment group(s) was
carried out using either a Student’s t test or one-way ANOVA, and statistical
significance is shown as described in the figure legends.
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